Dr Sznol on Frontline Standards of Care in Advanced or Metastatic Melanoma

“Although there are phase 3 trials that are ongoing, nothing [has been] proven better than those two combinations…in advanced [or] metastatic disease.”

Mario Sznol, MD, professor of clinical medical oncology at the Miller School of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discussed the current frontline systemic treatment landscape for patients with advanced or metastatic melanoma, with a focus on dual immune checkpoint blockade strategies that continue to define the standard of care in the United States.

Doublet immunotherapy, most commonly combining CTLA-4 and PD-1 inhibition, remains a cornerstone approach, Sznol explained. Regimens such as ipilimumab (Yervoy) plus nivolumab (Opdivo), as well as other PD-1–based combinations like nivolumab and relatlimab-rmbw (Opdualag), have consistently demonstrated improved progression-free survival compared with single-agent therapy alone. Importantly, although overall survival data continue to mature, there is a clear trend favoring these doublet approaches over single-agent checkpoint inhibition, Sznol added.

These efficacy signals have solidified dual immunotherapy as a preferred first-line option for patients with advanced or metastatic disease who are appropriate candidates for combination treatment. That said, the field remains committed to evaluating other strategies that may result in improved outcomes. For example, multiple ongoing phase 3 trials are evaluating novel combinations and sequencing strategies, including the addition of targeted agents or alternative immunotherapy backbones. Despite this momentum, no regimen has demonstrated superiority over the established doublet combinations, Sznol said.

In clinical decision-making today, factors such as patient performance status, comorbidities, and anticipated toxicity profiles remain critical when selecting therapy. Although combination immunotherapy offers improved disease control, it is also associated with higher rates of immune-related adverse effects vs monotherapy, necessitating careful patient selection and monitoring.

In summary, dual checkpoint inhibition continues to represent the benchmark for first-line treatment in advanced or metastatic disease, with ongoing research poised to refine but not yet replace this standard.